Valuation: Polaris Group

Market Cap 1.17TCr 37Cr 32Cr 30Cr 28Cr 52Cr 3.46TCr 53Cr 354.16Cr 137.47Cr 1.7TCr 137.48Cr 134.39Cr 5.95TCr P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 1.22TCr 38Cr 33Cr 31Cr 29Cr 54Cr 3.62TCr 55Cr 369.87Cr 143.57Cr 1.78TCr 143.58Cr 140.35Cr 6.21TCr EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
34.02%
Yield 2024 *
-
Yield 2025 -
1 day+2.26%
1 week+2.65%
Current month+0.37%
1 month+0.37%
3 months-30.87%
6 months-56.29%
Current year-56.43%
1 week 12.5
Extreme 12.5
13.6
1 month 12.5
Extreme 12.5
13.75
Current year 12.5
Extreme 12.5
35.95
1 year 12.5
Extreme 12.5
44.55
3 years 12.5
Extreme 12.5
91.1
5 years 12.5
Extreme 12.5
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%+2.65%-65.78%-83.73% 36Cr
+1.15%+9.07%-3.67%+4.36% 4.66TCr
-2.77%+12.95%+407.40%+614.26% 4.1TCr
-0.03%+15.14%+22.70%-12.74% 3.23TCr
-1.73%+4.85%+18.15%+59.57% 3.22TCr
-3.29%+2.85%+13.80%+30.30% 2.55TCr
+1.15%+16.98% - - 1.64TCr
-0.96%+16.22%+70.46%+125.41% 1.53TCr
+0.56%+8.00%+12.65%+21.35% 1.36TCr
-1.74%+4.48%+99.22%+92.87% 1.33TCr
Average -0.54%+9.29%+63.88%+94.63% 2.37TCr
Weighted average by Cap. -0.89%+10.35%+94.15%+141.05%

Financials

2024 2025
Net sales 11Cr 33.6L 29.38L 27.11L 25.3L 47.64L 32Cr 48.61L 3.25Cr 1.26Cr 16Cr 1.26Cr 1.23Cr 55Cr 4.06Cr 12.75L 11.15L 10.29L 10L 18.08L 12Cr 18.45L 1.23Cr 47.9L 5.94Cr 47.91L 46.83L 21Cr
Net income -250.26Cr -7.86Cr -6.87Cr -6.34Cr -5.92Cr -11Cr -743.93Cr -11Cr -76Cr -30Cr -366.16Cr -30Cr -29Cr -1.28TCr -392.71Cr -12Cr -11Cr -9.95Cr -9.29Cr -17Cr -1.17TCr -18Cr -119.37Cr -46Cr -574.58Cr -46Cr -45Cr -2.01TCr
Net Debt 91.92L 3L 3L 2L 2L 4L 2.73Cr 4L 27.94L 10.85L 1.34Cr 10.85L 10.6L 4.69Cr 52Cr 1.62Cr 1.42Cr 1.31Cr 1.22Cr 2.3Cr 153.65Cr 2.35Cr 16Cr 6.1Cr 76Cr 6.1Cr 5.96Cr 263.93Cr
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
30/26/30 NT$13.55 +2.26% 12,74,774
29/26/29 NT$13.25 +6.00% 15,13,600
26/26/26 NT$12.50 -4.21% 21,71,938
25/26/25 NT$13.05 -3.69% 12,46,733
24/26/24 NT$13.55 +3.44% 12,60,121
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock